4.650USD-1.48%Mkt Cap: 1.62B USDP/E: —Last update: 2026-05-26
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the trea…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap1.62B USD
Enterprise Value1.35B USD
Revenue (TTM)143.05M USD
Gross Profit53.60M USD
Net Income (TTM)-204.63M USD
Revenue/Share0.4160 USD
Last Price4.650 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees307
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-79.83
PEG—
EV/EBITDA-9.12
EV/Revenue9.45
P/S11.66
P/B5.43
EPS (TTM)-0.43
EPS (Forward)-0.06
52W Range
1.57038% of range9.750
52W High9.750 USD
52W Low1.570 USD
Profitability
Gross Margin85.22%
Oper. Margin4.66%
EBITDA Margin-103.61%
Profit Margin-325.31%
ROE-66.93%
ROA-34.40%
Growth
Revenue Growth2598.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-173.43M USD
CapEx (TTM)8.35M USD
FCF Margin-69.93%
FCF Yield-6.18%
Net Debt-316.74M USD
Net Debt/EBITDA2.14
Balance Sheet
Debt/Equity0.19
Current Ratio7.44
Quick Ratio7.04
Book Value/Sh0.8820 USD
Cash/Share1.533 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)12.33 USD
Target Range7.000 USD – 20.00 USD
# Analysts9
Ownership
Shares Out.347.20M
Float237.62M
Insiders18.59%
Institutions64.89%
Short Interest
Short Ratio15.1d
Short % Float24.07%
Short % Out.14.54%
Shares Short50.62M
Short (prev mo.)48.73M
Technical
SMA 504.582 (+1.5%)
SMA 2005.111 (-9.0%)
Beta1.52
S&P 52W Chg28.31%
Avg Vol (30d)4.25M
Avg Vol (10d)4.28M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—